The small molecular nanomolar casein kinase-2 inhibitor CX-4945 inhibits CLKs1–4 and exhibits anti-proliferative, anti-angiogenic and anti-tumour activity in mouse tumor xenograft models, inhibits PI3K/Akt signaling and HIF1α transcription, and is currently in clinical trials for bile duct cholangiocarcinoma, with gemcetibine and cisplatin [323]. The gene discussed is AKT1; the disease is neoplasm.